Julia Schmitt

Birkendorfer Str. 65
Biberach An Der Riss, BW 88400, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Artificial intelligence and radiomics biomarkers for treatment response prediction in advanced HER2-negative breast cancer.

Artificial intelligence and radiomics biomarkers for treatment response prediction in advanced HER2-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: February 09, 2025

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients.

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients.

Journal: Biomarker research

Published: February 08, 2024

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.

Journal: Theranostics

Published: December 03, 2020

Circadian rhythm impacts preclinical FDG-PET quantification in the brain, but not in xenograft tumors.

Circadian rhythm impacts preclinical FDG-PET quantification in the brain, but not in xenograft tumors.

Journal: Scientific reports

Published: August 22, 2019

Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids.

Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids.

Journal: Nuclear medicine and biology

Published: February 23, 2016

Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.

Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.

Journal: Oncotarget

Published: February 22, 2016

Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models.

Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models.

Journal: Cancer immunology, immunotherapy : CII

Published: December 23, 2015

Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.

Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.

Journal: Oncotarget

Published: December 21, 2015

Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Journal: Oncoimmunology

Published: December 16, 2014

Showing 1-9 of 9

Last Updated: 09/26/2026